Despite the long holiday weekend, news in biopharma never slows down. | This week on "The Top Line," we break down ...

A Philadelphia founder has been using artificial intelligence for life sciences materials since 2015, long before the mainstream hype for the tech.

One of the longstanding challenges in chemical biology has been finding ways to directly observe biological processes at work ...

After a three-year drought, the industry is questioning whether the window for medtech public offerings is open following a ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

The administration of US President Donald Trump has taken a series of actions since January, 2025 that directly threaten the ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

U.S. senator wants to know how the FDA will enforce drug ad regulations after letting go numerous workers from the office ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

2 M&A plays a key role in bringing highly lucrative medications to market, as large pharmaceutical companies often look to invest in young biotechnology companies for their innovative products.